Johnson & Johnson has reached a voluntary agreement with the Trump Administration to improve U.S. patient access to its medicines by cutting prices in exchange for exemptions from import tariffs. Under the deal, the company will offer selected pharmaceuticals at discounted rates via the TrumpRx.gov platform, match prices available in other developed markets and extend Medicaid pricing parity. The agreement covers dozens of branded therapies across immunology, oncology and neuroscience indications and is designed to benefit millions of Americans who face high out-of-pocket costs for specialty medicines.

As part of its broader U.S. strategy, Johnson & Johnson reaffirmed its previously announced $55 billion investment through early 2029 in domestic R&D, manufacturing and technology infrastructure. In the past ten months the company has initiated multiple projects, including two new facilities: a next-generation cell therapy plant in Pennsylvania and a state-of-the-art drug product site in North Carolina. Construction is also advancing on a $2 billion biologics manufacturing campus in Wilson, NC, expected to create 5,000 skilled jobs, while a 160,000-square-foot biopharmaceutical facility in Holly Springs will add approximately 120 positions over the next decade.

In its latest 13F filing, Almanack Investment Partners LLC increased its Johnson & Johnson stake by 29.6%, acquiring an additional 2,985 shares to bring its total to 13,074 shares, valued at $2.424 million as of quarter-end. Several smaller institutions also adjusted positions: Evolution Wealth Management initiated a $27,000 stake, Clayton Financial Group added $28,000, Semmax Financial Advisors boosted holdings by 55% to $31,000, and Signature Resources Capital Management more than tripled its stake to $47,000. Institutional investors and hedge funds now collectively own roughly 69.6% of the company’s outstanding shares.